Publications
148
Citations
1,732
Est. group size
~50
Recurring co-author estimate
Active years
30
Publishing since 1997
Karilyn Larkin's research focuses on blood and bone marrow transplantation, particularly for blood cancers like leukemia and myelodysplastic syndromes. Recent work examines how to reduce complications from transplants (such as graft-versus-host disease, where donor immune cells attack the recipient's body), improve donor matching options, and use immune profiling techniques to understand and predict transplant outcomes. This work often involves large multi-center clinical trials.
Publication output grew substantially from 2018 through 2021 and has since leveled off, remaining steady at around 18-19 publications per year through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study
Journal of Clinical Oncology · 2026
- Expanding Donor Access: Comparable One Year Outcomes in 4–6/8 and 7/8 Mismatched Unrelated Donor Transplantation with Ptcy-Based GVHD Prophylaxis (ACCESS Trial)
Transplantation and Cellular Therapy · 2026
- First Report of Successful, Lifesaving and Timely Graft Rescue Using an Off-the-Shelf Cryopreserved, Cadaveric Marrow in Myeloablative Transplant Following the Unexpected Unavailability of a Living Matched Unrelated Donor.
Transplantation and Cellular Therapy · 2026
- Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study
Blood · 2025
- A phase 1/2, first-in-human, multicenter, open-label trial evaluating the safety, tolerability, and antileukemic activity of Debio 1562M in patients with recurrent refractory acute myeloid leukemia (AML)
Blood · 2025
- Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.
Blood · 2025
- Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant
medRxiv · 2025
- Precision Oncology in Hematological Malignancies: Takeaways from the 2023 Precision Oncology Summit
International Journal of Cancer Care and Delivery · 2024
- Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study
Blood · 2023
- What is the role of leukopenia in the assessment of septic arthritis?
Journal of Orthopaedics · 2022
- Response to Letter to the Editor: A Comparison of Risk Factors for Septic Arthritis in Immunocompromised Patients: A Single Institution Study
Journal of the American Academy of Orthopaedic Surgeons · 2022
- Blood×48
- Transplantation and Cellular Therapy×20
- Journal of Clinical Oncology×10
- Blood Advances×8
- Leukemia×5
- Marcos J.G. De Lima
Medicine · The Ohio State University
- Gabriela Sanchez‐Petitto
Medicine · The Ohio State University
- Priyanka Mehta
Medicine · The Ohio State University
- Helee Desai
Medicine · The Ohio State University
- Alexander Rudich
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile